Bisphosphonates Prescription for Patients With Hip Fractures Based on Evaluation by a Dentist

• Published in: Curēus (Palo Alto, CA) Vol. 15; no. 2; p. e35407
• Main Authors: Inoue, Hayato, Oyama, Ryunosuke, Nakamura, Kimitaka, Inokuchi, Akihiko, Hamada, Takahiro, Izumi, Teiyu, Imamura, Ryuta, Ebihara, Toshihiro, Inoue, Takahiro, Arizono, Takeshi
• Format: Journal Article
• Language: English
• Published: United States Cureus Inc 24.02.2023; Cureus
• Subjects: Bisphosphonates; Dentistry; Dentists; Estrogens; Fractures; Hospitals; Intervention; Monoclonal antibodies; Necrosis; Oral hygiene; Orthopedics; Osteopathic Medicine; Osteoporosis; Physicians; Prescription drugs; Prevention; Surgeons; Japan; bisphosphonates; hip fractures; osteonecrosis of the jaw; clinical pathway; dentist
• ISSN: 2168-8184; 2168-8184
• DOI: 10.7759/cureus.35407

Background The purpose of this study is to clarify the current status of the prescription of postoperative bisphosphonates for patients with hip fractures and to explore the factors that prevent the postoperative prescription of bisphosphonates. Methods Of 180 patients with hip fractures treated surgically at our hospital between August 2019 and April 2020, 149 patients (46 men and 103 women; mean age: 83.9 ± 9.0 years), excluding 31 patients already prescribed bisphosphonates or denosumab, were included in the study. All patients were treated based on our clinical pathway, and their risk of jaw osteonecrosis was evaluated prior to the initiation of bisphosphonates by a dentist in our hospital. We collected data from the medical records on osteoporosis treatment interventions at admission and discharge, the reasons why postoperative bisphosphonates could not be prescribed at discharge, the proportion of patients who had follow-ups at our hospital, and patients' osteoporosis treatment status. Results Eighteen (12.8%) and 95 (63.8%) patients were prescribed anti-osteoporosis drugs at admission and discharge, respectively. One hundred and twenty-one patients (86.8%) could not be prescribed postoperative bisphosphonates at discharge - 71 (58.7%) because of oral hygiene problems, 34 (28.1%) because they did not have regular dental consultations, seven (5.8%) because of renal dysfunction, eight (6.6%) because of poor cognitive and swallowing function, and one (0.8%) because of medication side effects. Forty-nine patients (32.9%) went to our hospital for follow-up and 11 were introduced to bisphosphonates or denosumab at follow-up. Conclusions The number of patients with hip fractures who were prescribed postoperative bisphosphonates was low in our study. The oral hygiene problems identified by dentists accounted for responsible for the low prescription rate of postoperative bisphosphonates. Therefore, coordination with dentists may be important to increase the postoperative bisphosphonate prescription.